ArticleFrontiers in oncology2025
High expression of SOX10 is correlated with poor prognosis and immune infiltrates in skin cutaneous melanoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Melanoma stem cells drive macrophage reprogramming to a hybrid phenotype, modulating melanoma stemness and compromising NK cell-mediated immunity.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Skin Cutaneous Melanoma (SKCM) is a malignant tumor and the prediction of its prognosis remains challenging. Sex determining region Y-box 10 (SOX10) is over-expressed in SKCM and reported to accelerate tumor invasion and immunosuppression. Although studies have suggested the correlation of immune infiltration between SOX10 and SKCM, further in-depth explore of the immunomodulatory role of SOX10 is still needed. Therefore, we assessed the prognostic role of SOX10 and its correlation with immune infiltration and checkpoint expression. Methods: RNA sequencing data were obtained for analysis of SOX10 expression and differentially expressed genes (DEGs) from the Cancer Genome Atlas (TCGA). Moreover, functional enrichment analysis of SOX10-related DEGs was performed by GO/KEGG, GSEA. Receiver operating characteristic (ROC) curves were used to assess the diagnostic value of SOX10 in SKCM. Kaplan-Meier method was conducted to assess the effect of SOX10 on survival. Additionally, the clinical significance of SOX10 in SKCM was figured out by LASSO and prognostic nomogram model. We analyzed SOX10-related immune cell infiltration and expression of immune checkpoints. Finally, validations were performed through immunohistochemical analysis. Results: SOX10 was low expressed in a range of malignant tumor tissues except SKCM. Totally, 1029 differentially significant genes (DSGs) were identified between SOX10 low- and high- expression group, of which 50 genes were upregulated and 979 genes were downregulated. Additionally, SOX10 high expression was remarkably associated with pathologic stage, age and breslow depth in a sample of 472 cases (P Conclusion: Overall, high expression of SOX10 was correlated with poor prognosis in SKCM, which may be related to suppression of immune infiltration. The DSGs and pathways identified in our research have initially provided an insight into the molecular mechanisms underlying the progression of SKCM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.